This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

May 9, 2022

Company name: Modalis Therapeutics Corporation
Stock exchange listing: Tokyo Stock Exchange
Code number: 4883
URL: https://www.modalistx.com/en/
Representative: Haruhiko Morita,

Addition of MDL-105 to Our In-house Pipelines

Modalis Therapeutics Corporation (hereinafter the "Company") announces that it has decided to pursue development of MDL-105 as In-house pipelines.


MDL-105 is a novel gene therapy to treat dilated cardiomyopathy (DCM) by upregulating the Titin gene. Titin is the largest human protein, which consists of ~35,000 amino acids coded by 17kbp cDNA and is the third most abundant protein in muscle. It has been difficult to upregulate the expression of such large proteins with conventional technologies, but we were able to achieve this with our CRISPR-GNDM® technology. Historically, cardiomyopathy has been classified as a cardiovascular disease, but mechanistically it can be considered a muscular disease, and we believe that it is a plug-and-play indication to which our accumulated technologies and know-how in the area of muscular diseases can be directly applied.

MDL-105 is a pipeline that we have been researching in-house, and due to the scale of the disease, we have already received inquiries from several biotech companies and major pharmaceutical companies to consider partnering with us even though we are still in the early stages of development. The timing of the licensing agreement has not yet been determined.

In addition to the filing of a patent application, a reasonable evaluation of the business feasibility is required before the Company decides to include a newly developed product in In-house pipeline, which was approved by the Board of Directors today.

With the addition of MDL-105, we now have five products in In-house pipeline, and together with the three pipelines in Collaboration, we now have a total of eight products in our pipeline.

There will be minor impact on our business results for the current fiscal year.



*1: We have adopted a strategy of withholding specific indications until the patent application is published for competitive reasons.
*2: CMD1A=Merosin-deficient congenital muscular dystrophy type 1A
*3: Tauopathy belongs to a class of neurodegenerative diseases involving the aggregation of tau protein. Correlation with Alzheimer's disease has been suggested.
*4: DCM=Dilated cardiomyopathy